{"id":5653,"date":"2024-02-12T08:26:18","date_gmt":"2024-02-12T14:26:18","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5653"},"modified":"2025-06-27T11:21:50","modified_gmt":"2025-06-27T16:21:50","slug":"nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/","title":{"rendered":"Nanoscope anuncia presentaci\u00f3n en la 68.a reuni\u00f3n anual de la sociedad biof\u00edsica"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><strong>DALLAS<\/strong>, 12 de febrero de 2024 - <a href=\"https:\/\/nanostherapeutics.com\/es\/\">Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que Amir Singh, Ph.D. se presentar\u00e1 en el 68<sup>th<\/sup> <a href=\"https:\/\/www.biophysics.org\/2024meeting#\/\">Reuni\u00f3n anual de la sociedad biof\u00edsica<\/a> que tendr\u00e1 lugar del 10 al 14 de febrero de 2024 en el Centro de Convenciones de Pensilvania en Filadelfia. La reuni\u00f3n proporciona una plataforma para que los investigadores compartan sus \u00faltimos descubrimientos e innovaciones en biof\u00edsica.<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Singh profundizar\u00e1 en las caracter\u00edsticas biof\u00edsicas de la mol\u00e9cula MCO (MCO-010). Revelar\u00e1 el mecanismo de acci\u00f3n \u00fanico de MCO-010 al tiempo que detallar\u00e1 su bioinform\u00e1tica, estructura molecular y propiedades fotosensibles distintivas. La presentaci\u00f3n subraya la importancia de la investigaci\u00f3n biof\u00edsica y su impacto potencial en el avance de nuestra comprensi\u00f3n de las terapias de restauraci\u00f3n de la visi\u00f3n.<\/p>\n<p><strong>Detalles de presentaci\u00f3n<br \/>\n<\/strong><strong>T\u00edtulo: <\/strong>Esclarecer la singularidad estructural y funcional de la opsina multicaracter\u00edstica, una mol\u00e9cula sensible a la luz ambiental altamente dise\u00f1ada mediante bioingenier\u00eda, con capacidad de respuesta espectral de banda ancha y cin\u00e9tica r\u00e1pida para modular las actividades neuronales.<br \/>\n<strong>Fecha:<\/strong> mi\u00e9rcoles, 14 de febrero de 2024<br \/>\n<strong>Tiempo:<\/strong> 10:30 am hora del este<br \/>\n<strong>Ubicaci\u00f3n:<\/strong> Sala de exposiciones AB<br \/>\n<strong>Presentador:<\/strong> Dr. Amir Kumar Singh<\/p>\n<p>La estructura distintiva de MCO-010 permite funciones como una sensibilidad a la luz de banda ancha, un alto rango din\u00e1mico y una cin\u00e9tica de activaci\u00f3n r\u00e1pida, lo que lo convierte en una opci\u00f3n prometedora para restaurar la visi\u00f3n en personas con enfermedades degenerativas de la retina. Su capacidad para funcionar con luz ambiental sin dispositivos de estimulaci\u00f3n externos abre nuevas posibilidades para la restauraci\u00f3n de la visi\u00f3n. Este novedoso enfoque optogen\u00e9tico representa un avance significativo hacia el tratamiento de trastornos neurol\u00f3gicos que implican una actividad an\u00f3mala de los circuitos neuronales.<\/p>\n<p><strong>Acerca de MCO-010<\/strong><br \/>\nLas terapias gen\u00e9ticas actuales tienen como objetivo tratar a pacientes con mutaciones gen\u00e9ticas espec\u00edficas y est\u00e1n a\u00fan m\u00e1s limitadas en enfermedades avanzadas con c\u00e9lulas degeneradas de la retina externa. La monoterapia optogen\u00e9tica MCO activable con luz ambiental se dirige a abundantes neuronas internas de la retina y tiene el potencial de restaurar la visi\u00f3n perdida permanentemente debido a la RP avanzada. MCO-010 (<em>sonpiretigene isteparvovec<\/em>, suspensi\u00f3n para inyecci\u00f3n intrav\u00edtrea) es la \u00fanica opsina de banda ancha, r\u00e1pida y altamente sensible a la luz que se encuentra actualmente en ensayos cl\u00ednicos. Con orientaci\u00f3n a c\u00e9lulas bipolares mediante el potenciador del promotor mGluR6, el casete de expresi\u00f3n MCO-010 est\u00e1 dise\u00f1ado para restaurar la visi\u00f3n de alta calidad en entornos del mundo real. El vector patentado AAV2 permite una transducci\u00f3n robusta de MCO-010 en c\u00e9lulas bipolares tras inyecci\u00f3n intrav\u00edtrea. El estudio de fase 1\/2 de MCO-010 en pacientes con RP avanzada demostr\u00f3 una seguridad favorable y una mejora de la agudeza visual dependiente de la dosis. Se observaron mejoras nominalmente significativas en la agudeza visual en los pacientes tratados con MCO-010 en comparaci\u00f3n con el control en el ensayo RESTORE de fase 2b. Tambi\u00e9n hubo mejoras funcionales de la visi\u00f3n nominalmente significativas seg\u00fan lo evaluado por la movilidad guiada por visi\u00f3n de m\u00faltiples luminancias y la discriminaci\u00f3n de formas, junto con un perfil de seguridad favorable.<\/p>\n<p><strong>Acerca de Nanoscope Therapeutics, Inc.<br \/>\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina para las que no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04945772?term=Nanoscope&draw=2\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05417126?term=nanoscope&draw=2&rank=3\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><strong>Contacto de inversores:<\/strong><br \/>\n<strong>Socios Argot<\/strong><br \/>\n<strong>212-600-1902<\/strong><br \/>\n<a href=\"mailto:PR@nanostherapeutics.com\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS, February 12, 2024 \u2014 Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Amir Singh, Ph.D. will present at the 68th Annual Biophysical Society Meeting taking place from February 10-14, 2024, at the Pennsylvania Convention Center in Philadelphia. The meeting provides a platform for researchers to [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5655,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5653","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-12T14:26:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:21:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting\",\"datePublished\":\"2024-02-12T14:26:18+00:00\",\"dateModified\":\"2025-06-27T16:21:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/\"},\"wordCount\":511,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BiophysicalSociety.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/\",\"name\":\"Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BiophysicalSociety.jpg\",\"datePublished\":\"2024-02-12T14:26:18+00:00\",\"dateModified\":\"2025-06-27T16:21:50+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BiophysicalSociety.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BiophysicalSociety.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/12\\\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope anuncia su presentaci\u00f3n en la 68.\u00aa Reuni\u00f3n Anual de la Sociedad Biof\u00edsica - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-02-12T14:26:18+00:00","article_modified_time":"2025-06-27T16:21:50+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting","datePublished":"2024-02-12T14:26:18+00:00","dateModified":"2025-06-27T16:21:50+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/"},"wordCount":511,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/","url":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/","name":"Nanoscope anuncia su presentaci\u00f3n en la 68.\u00aa Reuni\u00f3n Anual de la Sociedad Biof\u00edsica - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg","datePublished":"2024-02-12T14:26:18+00:00","dateModified":"2025-06-27T16:21:50+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BiophysicalSociety.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/12\/nanoscope-announces-presentation-at-the-68th-annual-biophysical-society-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5653"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5653\/revisions"}],"predecessor-version":[{"id":9054,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5653\/revisions\/9054"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5655"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}